A Clinical Study to Access the Pharmacokinetics of HMS5552 in Renal Impaired Subjects and Healthy Volunteers

Inclusion Criteria: * For renal impaired subjects: 1. Male and female subjects between ages of 18 and 65 years, no less than 3 subjects in each gender. 2. Body weight≥50kg for male and ≥45kg for female； BMI: 18.5\~30 kg/m2 3. eGFR: P1 \< 15 mL/min/1.73 m2；P2: 15～29 mL/min/1.73 m2；P3: eGFR 30～59 mL/min/1.73 m2；P4: 60～89 mL/min/1.73 m2，and ACR≥ 3 mg/mmol； 4. Normal physical conditions, vital signs,12 lead ECG and laboratory recording, blood potassium 3.5\~5.5mmol/L; 5. Left ventricular ejection fraction (LVEF) ≥50% 6. Willing to sign the informed consent form (ICF) and take reliable contraceptive measures within 6 months after taking the last dose of study drug; 7. Willing to adhere to the protocol requirement. * For healthy volunteers: 1. Male and female subjects between ages of 18 and 65 years, no less than 3 subjects in each gender. 2. Body weight≥50kg for male and ≥45kg for female； BMI: 18.5\~30 kg/m2 3. MDRD eGFR: ≥90 mL/min/1.73 m2； 4. Gender, age (±5 years) and BMI (±15%) matched with corresponding subject in P1 group 5. Normal physical conditions, vital signs,12 lead ECG and laboratory recording 6. Systolic pressure: 90～140 mmHg，diastolic pressure:50～90 mmHg； 7. Willing to sign the informed consent form (ICF) and take reliable contraceptive measures within 6 months after taking the last dose of study drug; 8. Willing to adhere to the protocol requirement. Exclusion Criteria: * Subjects with impaired renal function cannot be enrolled if they meet one of the following criteria: 1. Acute renal failure; 2. History of allergy; 3. In addition to renal impaired function, investigators adjudicate subjects have diseases that may affect drug absorption, distribution, metabolism or excretion; 4. Any other disease may receive treatment or surgery during the study 5. Abnormal of ECG performance or laboratory recording; 6. Family history of QT prolongation syndrome; 7. Have unstable cardiovascular disease, lung disease, gastrointestinal disease, liver disease, blood disease, mental disease, nervous system disease, immune deficiency disease or any malignant tumor; 8. History of cardiovascular and cerebrovascular disease; 9. Hear failure (NYHA) class III or IV; 10. Severe anemia, CHC\<6.0g/dl at screening; 11. Severe infection, trauma, gastrointestinal operation or other surgery within 4 weeks before screening; 12. History of a) Type 1 diabetes, b) Acute complications of diabetes; 13. Serious hypoglycemia events within 3 months before screening; 14. More than 5 cigarettes per day within 3 months before screening; 15. Alcohol addicts; 16. History of drug abuse; * Healthy subjects cannot be enrolled if they meet one of the following criteria: 1. History of allergy; 2. Investigators adjudicate subjects have diseases that may affect drug absorption, distribution, metabolism or excretion; 3. Any other disease may receive treatment or surgery during the study 4. Abnormal of ECG performance or laboratory recording; 5. Family history of QT prolongation syndrome; 6. Have unstable cardiovascular disease, lung disease, gastrointestinal disease, liver disease, blood disease, mental disease, nervous system disease, immune deficiency disease or any malignant tumor; history of cardiovascular and cerebrovascular disease within 6 months before screening; severe infection, trauma, gastrointestinal operation or other surgery within 4 weeks before screening; 7. Anemia caused by any reason; 8. History of hypoglycemia (\<3.9mmol/L); 9. More than 5 cigarettes per day within 3 months before screening; 10. Alcohol addicts; 11. History of drug abuse;